Oramed Pharmaceuticals Inc. (ORMP) Develops Oral Drug DeliveryOramed Pharmaceuticals Inc. (ORMP) is developing oral drug delivery technologies that turn injectable treatments into easy-to-take pills. Its lead work focuses on oral insulin and other peptide medicines that could make managing chronic conditions far simpler for patients. Growth comes from advancin
Oramed Pharmaceuticals Inc.
No trades
No trades
Peers for comparison
4.23 USD
63.24 M USD
2.00 M USD
31.33 M
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Company info
Sector
Industry
CEO
Nadav Kidron
Website
Headquarters
New York
Founded
2002
IPO date
Apr 1, 2002
ISIN
US68403P2039
CUSIP
68403P203
FIGI
BBG000LRYR36
Identifiers
ISIN US68403P2039
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.
Oramed Pharmaceuticals Inc. (ORMP) Develops Oral Drug DeliveryOramed Pharmaceuticals Inc. (ORMP) is working on oral drug delivery technologies that turn injections into easy-to-take pills. Its main focus is developing oral insulin and other oral peptide treatments that could reshape how chronic conditions are managed. Growth leans on advancing clinical studies
ORMP Possible SupportHere is the monthly chart of ORMP. They came out with bad news on their leading drug today. Looking at the chart the area that price stopped has been support historically. I bought in at 2.53 and will hold for a while. Exit around 4 seems to be a good trade based on previous data.
Not financial adv
Preparing to conduct clinical trials for an ORAL Covid vaccineThis could be interesting. I am sure there are numerous companies racing to see if they can get an oral version of a Covid vaccine out into the market and especially booster tablets.
Oramed focuses on making oral delivery solutions for drugs typically delivered via injection. Its current focuses
ORMP (ORAMED PHARMACEUTICALS Inc.) - False BreakMarket structure: Uptrend, price might retest previous resistance turn support
Setup: False Break/ Retest previous resistance turn support
False Break candlestick pattern: Hammer / Bullish engulfing
To look for trading opportunities when price retest previous resistance turn support at around 14.40
ORMP by request KeyCode 2 Possible PathsI made a key code of the price action then found an exact match to this move in the past.... one that matched at lease 95% or better. That way if the move is that close to the same shape we have now it must mean the sentiment of the market was the same at that time. Therefore, the outcome should be
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
Oscillators
Neutral
Summary
Neutral
Summary
Neutral
Summary
Neutral
Moving Averages
Neutral
Moving Averages
Neutral
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently asked questions
Today, ORMP trades at 3.96 USD.
For broader market analysis, dive into the technicals on the Oramed Pharmaceuticals Inc. stock price chart and read the latest ORMP news:
– ORMP Q3'26 Earnings: revenue estimate is 0 USD
– ORMP Q2'26 Earnings: EPS estimate is 0.43 USD
– Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
For broader market analysis, dive into the technicals on the Oramed Pharmaceuticals Inc. stock price chart and read the latest ORMP news:
– ORMP Q3'26 Earnings: revenue estimate is 0 USD
– ORMP Q2'26 Earnings: EPS estimate is 0.43 USD
– Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
Markets don't sleep, here's what's going on with ORMP at the moment:
– ORMP Q3'26 Earnings: revenue estimate is 0 USD
– ORMP Q2'26 Earnings: EPS estimate is 0.43 USD
– Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
See more updates in real-time with our News Flow.
– ORMP Q3'26 Earnings: revenue estimate is 0 USD
– ORMP Q2'26 Earnings: EPS estimate is 0.43 USD
– Oramed Pharmaceuticals Inc expected to post earnings of 43 cents a share - Earnings Preview
See more updates in real-time with our News Flow.
Oramed Pharmaceuticals Inc. is scheduled to release its next earnings report on Nov 16, 2026.
Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release
How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
Why it matters:
– Key event: Earnings often drive significant price moves
– Market expectations: Traders watch revenue, EPS, and guidance vs forecasts
– Volatility spike: Price swings can increase before and after the release
How to use it:
– Track upcoming reports in the Earnings Calendar
– Compare actual results with analyst estimates
– Monitor price reaction and volume on Supercharts
ORMP stock is 3.64% volatile and has beta coefficient of 0.85.
What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable
Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like ORMP are typically less volatile than smaller companies
Track every detail on Oramed Pharmaceuticals Inc. stock chart and check out the list of the most volatile stocks — is Oramed Pharmaceuticals Inc. there?
What it means:
– Volatility: Shows how much the price fluctuates over time
– Beta > 1: More volatile than the market
– Beta < 1: Less volatile, more stable
Important to know:
– Volatility can increase during earnings, news events, or market stress
– Large-cap stocks like ORMP are typically less volatile than smaller companies
Track every detail on Oramed Pharmaceuticals Inc. stock chart and check out the list of the most volatile stocks — is Oramed Pharmaceuticals Inc. there?
To understand the ORMP stock performance, it's worth checking price changes for various periods to get the full picture:
– 1 day — +2.52%
– 1 week — −3.72%
– 1 month — −5.11%
ORMP all-time low was 0.09 USD (Apr 2, 2004), and its highest price is 31.73 USD (Jan 13, 2014). Find more dynamics in the Stock Heatmap and on the Oramed Pharmaceuticals Inc. stock chart.
– 1 day — +2.52%
– 1 week — −3.72%
– 1 month — −5.11%
ORMP all-time low was 0.09 USD (Apr 2, 2004), and its highest price is 31.73 USD (Jan 13, 2014). Find more dynamics in the Stock Heatmap and on the Oramed Pharmaceuticals Inc. stock chart.
Oramed Pharmaceuticals Inc. market capitalization is 160.57 M, representing the total value of all its outstanding shares (price × shares outstanding).
What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements
What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Oramed Pharmaceuticals Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Oramed Pharmaceuticals Inc. stacks up against other companies
What it means:
– Market cap is one of the key ways to classify companies (large-cap, mid-cap, etc.)
– It reflects how investors value the company today
– It changes constantly with stock price movements
What to look at next:
– Market cap trends: Rising cap may signal growth and investor confidence; falling cap can reflect risk or downturns
– Price vs shares: Changes can come from Oramed Pharmaceuticals Inc. stock price moves or share count (buybacks, issuance)
– Valuation ratios: Compare market cap with revenue and earnings
– Peer comparison: See how Oramed Pharmaceuticals Inc. stacks up against other companies
The safest way to buy Oramed Pharmaceuticals Inc. stocks is through a reliable broker. Create an account, fund it, and place a buy order.
You can trade ORMP directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart
Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
You can trade ORMP directly from TradingView:
– Choose a broker: Explore our supported trading partners and pick one that fits your needs
– Compare options: View available brokers side by side to evaluate fees and features
– Connect your account: Open Supercharts, click “Trade”, select your broker, and log in
– Start trading: Place orders without leaving the chart
Tip: If you’re new to trading, try paper trading first — it lets you practice strategies in real market conditions without risking funds.
As of Nov 9, 2026, the company has 13 employees.
Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements
See our rating of the largest employers to find more opportunities.
Why traders follow this data:
– Company scale: Employee count reflects the size and global reach of the business
– Operational footprint: Higher headcount often indicates broader product lines, retail presence, or services
– Trend signal: Changes over time can reflect hiring growth, restructuring, or efficiency improvements
See our rating of the largest employers to find more opportunities.
Investing in Oramed Pharmaceuticals Inc. depends on your goals, risk tolerance, and market conditions. It’s essential to analyze the stock before making a decision.
First, study Oramed Pharmaceuticals Inc. financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency
Then explore our ORMP technicals – signals based on essential indicators calculations:
– Today — sell
– 1-week — buy
– 1-month — sell
Combine fundamental and technical analysis for better results.
First, study Oramed Pharmaceuticals Inc. financials and track their dynamics on the Fundamental Graphs:
– Business fundamentals: Revenue, earnings, and growth trends
– Valuation: P/E ratio, market cap, and how it compares to peers
– Profitability: Margins, return on equity, and cash flow
– Dividends (if any): Yield, payout ratio, and consistency
Then explore our ORMP technicals – signals based on essential indicators calculations:
– Today — sell
– 1-week — buy
– 1-month — sell
Combine fundamental and technical analysis for better results.
Oramed Pharmaceuticals Inc. stock ticker depends on the exchange where it’s listed. On the NASDAQ, its primary exchange, Oramed Pharmaceuticals Inc. stocks trade under the symbol ORMP.
About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners
Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion
Learn how to find your desired assets in our Symbol Search.
About tickers:
– Unique identifiers: A ticker is a short code used to find and trade a stock
– Exchange-specific: The same company may have different tickers across exchanges
– Search shortcut: Used on trading platforms, charts, and screeners
Remember:
– Some companies have multiple listings
– Always check the exchange prefix to avoid confusion
Learn how to find your desired assets in our Symbol Search.
ORMP earnings for the last quarter are 2.76 USD per share, whereas the estimation was 0.43 USD, resulting in a 541.86% surprise. The estimated earnings for the next quarter are 0.43 USD per share.
How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one
Follow other essential metrics in Oramed Pharmaceuticals Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk
How to read financials:
– Compare actual vs estimates: Earnings beats or misses often drive price moves
– Watch market reaction: Price response matters as much as the numbers
– Look at forward guidance: Future estimates signal expected growth
– Track trends: Analyze results across multiple quarters, not just one
Follow other essential metrics in Oramed Pharmaceuticals Inc. financials:
– Revenue growth: Shows business expansion
– Margins (operating, net): Reflect profitability and efficiency
– Free cash flow: Indicates real cash generation
– Debt levels: Impacts financial stability and risk
Oramed Pharmaceuticals Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
What it might mean:
– Stable demand: Sales are holding steady without clear growth or decline
– Mature business phase: Growth may be slowing in core segments
– Offsetting factors: Strength in some areas may be balancing weakness in others
What to look at next in Oramed Pharmaceuticals Inc. financials:
– Margins: Profitability may improve or decline even if revenue is flat
– Net income & EPS: Cost control or share buybacks can still drive earnings changes
– Segment breakdown: Some business lines may be growing while others shrink
What it might mean:
– Stable demand: Sales are holding steady without clear growth or decline
– Mature business phase: Growth may be slowing in core segments
– Offsetting factors: Strength in some areas may be balancing weakness in others
What to look at next in Oramed Pharmaceuticals Inc. financials:
– Margins: Profitability may improve or decline even if revenue is flat
– Net income & EPS: Cost control or share buybacks can still drive earnings changes
– Segment breakdown: Some business lines may be growing while others shrink
Yes, you can track Oramed Pharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
Use our Earnings Calendar to never miss important releases and spot opportunities early.
Use our Earnings Calendar to never miss important releases and spot opportunities early.
ORMP net income for the last quarter is 78.16 M USD, while the quarter before that showed 38.31 M USD of net income which accounts for 104.01% change.
How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result
Follow other essential metrics in Oramed Pharmaceuticals Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
How to read this data:
– Track changes: Compare net income across quarters to spot trends
– Watch expectations: Compare with estimates to gauge performance
– Check margins: Net income reflects profitability after all expenses
– Look beyond one quarter: Consistency matters more than a single result
Follow other essential metrics in Oramed Pharmaceuticals Inc. financials:
– Revenue: Overall business growth
– Earnings per share: Rising EPS over time often points to improving business performance
– Margins (gross, operating): Efficiency and cost control
ORMP reached its all-time high of 31.73 USD on Jan 13, 2014. Its all-time low was 0.09 USD and was reached on Apr 2, 2004.
Explore the Oramed Pharmaceuticals Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Explore the Oramed Pharmaceuticals Inc. stock price chart to see more price history, and discover companies reaching new all-time highs and lows.
Oramed Pharmaceuticals Inc. EBITDA is −14.40 M USD, with an EBITDA margin of −748.35%.
EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.
What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures
What to look at next in Oramed Pharmaceuticals Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality
EBITDA is a measure of core operating performance, showing how much profit the company generates from its main business activities before accounting for financing and accounting-related costs.
What it means:
– Operating strength: Helps assess profitability from core operations
– Efficiency signal: Rising EBITDA often reflects improving business performance
– Comparability: Useful for comparing companies with different capital structures
What to look at next in Oramed Pharmaceuticals Inc. statements:
– Revenue growth: Shows whether the business is expanding
– Net income: Captures full profitability after all expenses
– Free cash flow: Shows actual cash generated
– Debt levels: Important when evaluating earnings quality
Analyst forecasts suggest a price range between 7.00 USD and 7.00 USD for ORMP, based on current estimates.
Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions
Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance
Remember:
– Forecasts show possible scenarios, not guaranteed outcomes
– They're based on multiple analysts’ models and assumptions
– Target prices change with earnings, news, and market conditions
Don't rely on analysts' opinions alone:
– Use technical analysis: Trend, support/resistance, momentum
– Study fundamentals: Revenue, earnings, margins
– Account for market context: News, macro trends, sector performance









